We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.01B
AUM Growth
-$402M
Cap. Flow
-$269M
Cap. Flow %
-26.61%
Top 10 Hldgs %
65.73%
Holding
37
New
7
Increased
7
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$65.3M
2
GMED icon
Globus Medical
GMED
+$62.5M
3
ALGN icon
Align Technology
ALGN
+$62.2M
4
ARQL
Arqule Inc
ARQL
+$37.2M
5
STAA icon
STAAR Surgical
STAA
+$22.6M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$122M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$92.3M
3
URGN icon
UroGen Pharma
URGN
+$51.5M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$51.1M
5
AERI
Aerie Pharmaceuticals
AERI
+$44.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$298M
$96.9M 9.59%
319,513
-111,178
-26% -$38.8M
CPRX
2
DELISTED
Catalyst Pharmaceutical
CPRX
$94.9M 9.39%
17,875,655
– –
UTHR icon
3
United Therapeutics
UTHR
$26.2B
$77.2M 7.64%
967,569
+196,800
+26% +$15.8M
GMED icon
4
Globus Medical
GMED
$10.9B
$67.1M 6.64%
+1,313,177
New +$62.5M
TNDM icon
5
Tandem Diabetes Care
TNDM
$1.3B
$60.3M 5.97%
+1,022,257
New +$65.3M
QURE icon
6
uniQure
QURE
$2.93B
$56.2M 5.56%
1,428,202
-483,327
-25% -$27.9M
KPTI icon
7
Karyopharm Therapeutics
KPTI
$159M
$56.2M 5.56%
389,162
+2,280
+0.6% +$309K
VCEL icon
8
Vericel Corp
VCEL
$2.43B
$55.2M 5.46%
3,644,492
+712,340
+24% +$12.5M
ALGN icon
9
Align Technology
ALGN
$12.4B
$54.1M 5.35%
+299,000
New +$62.2M
OMER icon
10
Omeros
OMER
$863M
$46.2M 4.57%
2,831,109
-220,813
-7% -$3.79M
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$41M 4.06%
3,975,054
-785,005
-16% -$9.9M
OXFD
12
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$35.7M 3.53%
2,144,524
-199,000
-8% -$2.75M
STAA icon
13
STAAR Surgical
STAA
$1.21B
$31.7M 3.13%
1,227,771
+743,214
+153% +$22.6M
IOVA icon
14
Iovance Biotherapeutics
IOVA
$2.09B
$30.6M 3.02%
1,679,327
-4,173,509
-71% -$92.3M
ARQL
15
DELISTED
Arqule Inc
ARQL
$28.8M 2.85%
4,011,342
+3,961,342
+7,923% +$37.2M
KDMN
16
DELISTED
Kadmon Holdings, Inc.
KDMN
$26.9M 2.67%
10,693,574
-934,326
-8% -$2.32M
TVTX icon
17
Travere Therapeutics
TVTX
$5.33B
$26.8M 2.65%
2,314,421
-1,498,095
-39% -$24.8M
PODD icon
18
Insulet
PODD
$11.5B
$25.7M 2.54%
+155,800
New +$21.9M
ADMA icon
19
ADMA Biologics
ADMA
$2.01B
$22.8M 2.25%
5,114,986
-590,366
-10% -$2.47M
CDNA icon
20
CareDx
CDNA
$1.97B
$16.4M 1.62%
+726,128
New +$20.1M
AUPH icon
21
Aurinia Pharmaceuticals
AUPH
$1.93B
$13.7M 1.35%
2,561,269
-1,661,289
-39% -$10.1M
CCXI
22
DELISTED
ChemoCentryx, Inc.
CCXI
$11.3M 1.12%
1,666,667
– –
ANIP icon
23
ANI Pharmaceuticals
ANIP
$1.83B
$10.4M 1.03%
142,943
– –
MBIO icon
24
Mustang Bio
MBIO
$4.5M
$10.3M 1.02%
4,213
-287
-6% -$785K
KRYS icon
25
Krystal Biotech
KRYS
$10.8B
$7.78M 0.77%
224,090
+42,000
+23% +$1.88M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Consonance Capital Management held 37 positions worth $1.01B, down 28% from $1.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Consonance Capital Management withdrew a net $269M in Q3 2019, closing 7 positions and reducing 12 holdings. Its most notable exit was Pacira BioSciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Tandem Diabetes Care worth $60.3M.

  • Consonance Capital Management's largest Q3 2019 buy was Tandem Diabetes Care: 1,022,257 shares worth $60.3M.
  • Consonance Capital Management added most to Arqule Inc in Q3 2019, an estimated $37.2M increase.
  • Consonance Capital Management's biggest Q3 2019 reduction was Iovance Biotherapeutics, cutting an estimated $92.3M.
  • Consonance Capital Management fully exited Pacira BioSciences in Q3 2019, selling an estimated $122M.
  • Consonance Capital Management's ten largest holdings make up 66% of its $1.01B portfolio in Q3 2019.
  • Consonance Capital Management opened 7 new positions and closed 7 in Q3 2019.
  • Consonance Capital Management's portfolio value fell 28% quarter-over-quarter to $1.01B.

Based on Consonance Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.